1KJ Stock Overview A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
10x Genomics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for 10x Genomics Historical stock prices Current Share Price US$12.78 52 Week High US$46.23 52 Week Low US$12.22 Beta 1.82 1 Month Change -9.65% 3 Month Change -40.14% 1 Year Change -74.58% 3 Year Change -89.31% 5 Year Change -80.34% Change since IPO -73.58%
Recent News & Updates
Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.79 loss in 3Q 2023) Oct 30
10x Genomics, Inc. Announces Launch of Two New Chromium Products Intends to Democratize Access to Single Cell Analysis - GEM-X Flex and GEM-X Universal Multiplex Oct 16
10x Genomics, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 10
10x Genomics, Inc. Announces Launch of Chromium Xo, A New Addition to Its Fleet of Chromium Single Cell Instruments Sep 04
New minor risk - Shareholder dilution Aug 10 10X Genomics, Inc. Revises Earnings Guidance for Full Year 2024 Aug 09
See more updates
Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.79 loss in 3Q 2023) Oct 30
10x Genomics, Inc. Announces Launch of Two New Chromium Products Intends to Democratize Access to Single Cell Analysis - GEM-X Flex and GEM-X Universal Multiplex Oct 16
10x Genomics, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 10
10x Genomics, Inc. Announces Launch of Chromium Xo, A New Addition to Its Fleet of Chromium Single Cell Instruments Sep 04
New minor risk - Shareholder dilution Aug 10 10X Genomics, Inc. Revises Earnings Guidance for Full Year 2024 Aug 09
10x Genomics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 13
Insufficient new directors Jun 10
10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium May 30
10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024 May 03
First quarter 2024 earnings released: US$0.50 loss per share (vs US$0.44 loss in 1Q 2023) May 02
Insufficient new directors May 02
10x Genomics, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
10x Genomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 11
10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay Mar 27
10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel Mar 22
10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products Mar 14
Full year 2023 earnings released: US$2.18 loss per share (vs US$1.46 loss in FY 2022) Feb 16 10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024 Feb 16
Insufficient new directors Feb 14
10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology Feb 08
10x Genomics, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 25
James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024 Jan 17
New minor risk - Profitability Jan 05
Forecast to breakeven in 2026 Dec 31
Insufficient new directors Dec 05
Chief Commercial Officer recently sold €566k worth of stock Nov 25
Third quarter 2023 earnings released: US$0.79 loss per share (vs US$0.37 loss in 3Q 2022) Nov 08
Insufficient new directors Nov 08
10X Genomics, Inc. Raises Revenue Guidance for Full Year 2023 Nov 03
10X Genomics, Inc. Announces Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors Oct 28
10x Genomics, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 12
10x Genomics, Inc. Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit Sep 15
10X Genomics, Inc. Announces Use of Its Technologies in A Study Published in the Journal of Clinical Investment Sep 06
Chief Commercial Officer recently sold €409k worth of stock Aug 27
Insufficient new directors Aug 14
Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.57 loss in 2Q 2022) Aug 05
10x Genomics, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 04
10X Genomics, Inc. Announces Board Changes Jul 23
Insufficient new directors Jul 18
10x Genomics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 14
Vizgen, Inc. Provides Update on Litigation Jul 12 10x Genomics, Inc.(NasdaqGS:TXG) dropped from Russell Small Cap Comp Value Index
Independent Chairman recently sold €512k worth of stock Jun 12
Co-Founder recently sold €133k worth of stock May 26
No longer forecast to breakeven May 19
Insufficient new directors May 19
No longer forecast to breakeven May 05
10X Genomics, Inc. Revises Revenue Guidance for the Full Year 2023 May 05
First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2022) May 04
Forecast to breakeven in 2025 Apr 11
Insufficient new directors Mar 24
Co-Founder recently sold €87k worth of stock Mar 01
Full year 2022 earnings released: US$1.46 loss per share (vs US$0.53 loss in FY 2021) Feb 17
10x Genomics, Inc. Provides Revenue Guidance for the Full Year 2023 Feb 16
10x Genomics, Inc. to Report Q4, 2022 Results on Feb 15, 2023 Jan 20
Insufficient new directors Jan 11
10x Genomics, Inc. Launches Xenium Platform for In Situ Analysis Dec 10
Co-Founder recently sold €89k worth of stock Nov 25
Insufficient new directors Nov 16
10X Genomics, Inc. Announces Commercial Availability of BEAM Nov 10
Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.15 loss in 3Q 2021) Nov 05
10X Genomics, Inc. Provides Revenue Guidance for Full Year 2022 Nov 03
10x Genomics, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 13
Insufficient new directors Sep 02
Co-Founder recently sold €96k worth of stock Aug 27
No longer forecast to breakeven Aug 11
Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.10 loss in 2Q 2021) Aug 10
10X Genomics, Inc. Provides Earnings Guidance for the Third Quarter of 2022 and Full Year 2022 Aug 09 10x Genomics, Inc. to Report Q2, 2022 Results on Aug 08, 2022
10x Genomics Inc. Advances Leadership and Innovation in Single Cell and Spatial Technologies At 2022 AGBT General Meeting Jun 08
First quarter 2022 earnings released: US$0.38 loss per share (vs US$0.11 loss in 1Q 2021) May 06
10x Genomics, Inc. Maintains Revenue Guidance for Full Year 2022 May 05
10x Genomics, Inc., Annual General Meeting, Jun 15, 2022 May 02
Forecast breakeven date pushed back to 2024 Apr 27
10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium Apr 15
10x Genomics, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 08
Forecast breakeven date pushed back to 2024 Mar 08
10X Genomics, Inc. Showcases Robust Innovation Pipeline at Xperience 2022 Event Feb 24
Forecast breakeven date pushed back to 2024 Feb 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 17
10x Genomics, Inc. Provides Revenue Guidance for the Full Year of 2022 Feb 17
10X Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network Jan 22
Forecast to breakeven in 2023 Sep 23
10x Genomics, Inc. Maintains Revenue Guidance for 2021 Aug 06
Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.41 loss in 2Q 2020) Aug 05
10X Genomics Introduces New Chromium X Series for Single Cell Analysis Jul 15
10x Genomics, Inc. Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay Jun 11
Co-Founder recently sold €103k worth of stock May 28
First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.22 loss in 1Q 2020) May 06
10x Genomics, Inc. Provides Revenue Guidance for the Full Year 2021 May 06
10x Genomics, Inc. (NasdaqGS:TXG) acquired Tetramer Shop Aps. Feb 26
Full year 2020 earnings released Feb 19
Revenue beats expectations Feb 19 Shareholder Returns 1KJ DE Life Sciences DE Market 7D -7.2% -1.4% -1.6% 1Y -74.6% -5.5% 6.8%
See full shareholder returns
Return vs Market: 1KJ underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is 1KJ's price volatile compared to industry and market? 1KJ volatility 1KJ Average Weekly Movement n/a Life Sciences Industry Average Movement 7.1% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1KJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 1KJ's volatility change over the past year.
About the Company 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell.
Show more 10x Genomics, Inc. Fundamentals Summary How do 10x Genomics's earnings and revenue compare to its market cap? 1KJ fundamental statistics Market cap €1.71b Earnings (TTM ) -€175.45m Revenue (TTM ) €605.25m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1KJ income statement (TTM ) Revenue US$629.74m Cost of Revenue US$210.13m Gross Profit US$419.61m Other Expenses US$602.16m Earnings -US$182.55m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 12:19 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources 10x Genomics, Inc. is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Luke Sergott Barclays Michael Ryskin BofA Global Research
Show 20 more analysts 
